Last updated on October 2018

Safety and Compliance of Renal Cancer Patients Treated by Non-IV Drugs


Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: Stage III Renal Cell Cancer | Metastatic or Advanced Renal Cancer | Metastatic Renal Cancer
  • Age: Between 18 - 100 Years
  • Gender: Male or Female

Inclusion Criteria:

  • Adult patient
  • Patient with metastatic or locally advanced kidney cancer
  • Patient initiating for the first time an oral route anticancer drug : Sutent (sunitinib), Nexavar (sorafenib), Afinitor (everolimus), Votrient (pazopanib) and Inlyta (axitinib) and Cabometyx (cabozantinib)
  • Patient having signed an informed consent
  • Patient treated outside interventional clinical trial

Exclusion Criteria:

  • Patient with cancer other than kidney cancer
  • Patient with non-extensive kidney cancer
  • Patient treated by surgery, radiotherapy and intravenous chemotherapy exclusively
  • Patient unable to undergo protocol monitoring
  • Patient included in an interventional trial
  • Patient refusing a survey at home or having hearing problems
  • Other medical conditions that may interfere with the understanding of the informed consent document, with the assessment of tolerance and the response to questionnaires
  • Patient with another condition deemed incompatible with the patient's inclusion into the protocol.
  • Patient under guardianship or trusteeship, deprived of liberty, underage patient or pregnant woman
  • Patient not affiliated with a social security system beneficiary of such a scheme

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.